AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reiterated by research analysts at Liberum Capital in a research report issued to clients and investors on Monday. They presently have a GBX 4,800 ($62.31) target price on the biopharmaceutical company’s stock. Liberum Capital’s target price suggests a potential upside of 8.65% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Citigroup Inc. reissued a “buy” rating and issued a GBX 6,000 ($77.89) price target on shares of AstraZeneca plc in a research note on Thursday, July 13th. Deutsche Bank AG dropped their price target on AstraZeneca plc from GBX 5,500 ($71.40) to GBX 5,350 ($69.45) and set a “buy” rating on the stock in a research note on Friday, April 28th. Barclays PLC reissued an “overweight” rating and issued a GBX 6,000 ($77.89) price target on shares of AstraZeneca plc in a research note on Friday, April 28th. Jefferies Group LLC dropped their price target on AstraZeneca plc from GBX 5,500 ($71.40) to GBX 5,300 ($68.80) and set a “hold” rating on the stock in a research note on Wednesday, July 12th. Finally, HSBC Holdings plc lowered AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($58.42) price target on the stock. in a research note on Tuesday, July 4th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of GBX 4,899.33 ($63.60).

Shares of AstraZeneca plc (AZN) traded down 0.65% during trading on Monday, hitting GBX 4418.00. 1,240,031 shares of the stock traded hands. The company has a 50-day moving average of GBX 4,788.92 and a 200-day moving average of GBX 4,872.63. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The firm’s market cap is GBX 55.93 billion.

ILLEGAL ACTIVITY NOTICE: “AstraZeneca plc’s (AZN) Buy Rating Reaffirmed at Liberum Capital” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/21/astrazeneca-plcs-azn-buy-rating-reaffirmed-at-liberum-capital.html.

In related news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average price of GBX 4,370 ($56.73) per share, with a total value of £1,704.30 ($2,212.51).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.